U.S. Markets closed

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 13, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. ("Stemline" or the "Company") (STML) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired Stemline shares between January 19, 2017 and February 1, 2017, inclusive (the "Class Period"), are encouraged to contact the firm in advance of the April 4, 2017 lead plaintiff deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

On February 2, 2017, Bloomberg confirmed that a patient undergoing a clinical trial of Stemline's cancer drug SL-401 died from a severe side effect, the third death related to SL-401 toxicity.

When this information was revealed to the public, the value of Stemline stock fell sharply, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125

SOURCE: Lundin Law PC